FDA Will Require Additional Long-Term Data For COX-2 Inhibitors

“It’s really premature for us to say right now how our requirements are going to change,” CDER Acting Director Galson says. However, the agency will “ask for more long-term data” for COX-2 inhibitors in the pipeline and those already on the market in the wake of the Vioxx withdrawal.